|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Tick-borne Disease, Acute Molecular Panel
Test Code94322
Includes
Anaplasma Phagocytophilum DNA, Qualitative Real-Time PCR
Babesia microti DNA, Real-Time PCR
Borrelia miyamotoi DNA, Real-Time PCR,
Ehrlichia chaffeensis DNA, Real-Time PCR
Borrelia Species DNA, Qualitative Real-Time PCR
Babesia microti DNA, Real-Time PCR
Borrelia miyamotoi DNA, Real-Time PCR,
Ehrlichia chaffeensis DNA, Real-Time PCR
Borrelia Species DNA, Qualitative Real-Time PCR
Preferred Specimen
Lavender Top
Minimum Volume
1.5 mL
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 30 days
Refrigerated: 7 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Lithium heparin (green-top) tube • Sodium heparin (green-top) tube
Methodology
Real-Time Polymerase Chain Reaction
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon-Sat; Report available: 1-3 days
Reference Range
See Laboratory Report
Clinical Significance
Persons infected with Borrelia miyamotoi most likely have fever, joint pains, fatigue, and headache, though unlike Lyme disease, rash is uncommon.
The diagnosis of Borrelia miyamotoi is most often made by history and clinical examination combined with exposure in endemic areas. Amplification of B. miyamotoi genomic DNA from blood, fluids or tissues confirms the diagnosis.
The diagnosis of Borrelia miyamotoi is most often made by history and clinical examination combined with exposure in endemic areas. Amplification of B. miyamotoi genomic DNA from blood, fluids or tissues confirms the diagnosis.
